Hypokalemia in Hospitalized COVID-19 Patients: Prevalence and Correlates
John Omotola Ogunkoya, Emmanuel Fikayo Bamidele, Peter Kehinde Uduagbamen, Akindele Emmanuel Ladele, Taamaka Davis Ngubor, Solomon Olubunmi Eigbe, Boluwatife Adetoyin Adeboye
Journal of Advances in Medicine and Medical Research · pp. 44–53 · Published 12 Sep 2022
10.9734/jammr/2022/v34i2231577Abstract
Objectives: This study was designed to evaluate the prevalence, and the severity of hypokalemia, and the factors associated with hypokalemia among patients hospitalized with COVID-19. Methods: Random sampling technique was employed in this study. Socio-demographic data such as age, gender, weight (kg), height (meters) and BMI (kg/m2) as well as presenting symptoms (pulmonary and extra-pulmonary), duration of admission, the need for mechanical ventilation and treatment outcomes (discharged or died) as well as the plasma level of potassium (mmol/l) were extracted from the medical records of RT-PCR confirmed hospitalized cases of COVID-19 patients. Data collected were analyzed with IBM/ SPSS version 25.0 software. Discrete variables were presented as percentages and frequencies and the associations between qualitative variables tested using the Chi-square test at a level of significance of p < 0.05. Results: Hypokalaemia was detected in 61 out of 117 COVID-19 positive subjects used for this study during hospitalization. The mean serum potassium was 3.45±0.633 mmol/L. The majority of hypokalemic patients (n=35, 29.9%) patients experienced a mild decrease in serum potassium level (3–3.4 mmol/L). Risk factors for hypokalaemia were female sex and patients presenting with sneezing or/and sore throat. There was no relationship between the plasma potassium level and comorbid factors. There was no increasing trend of 30-day mortality associated with lower plasma potassium level. Conclusion: Plasma potassium levels should be monitored routinely and maintained within appropriate ranges in patients with COVID-19 especially in female patients as well as patient with significant upper respiratory symptoms such as sore throat and sneezing.
Cited by 0
No indexed citations yet.
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.